Ascendis Pharma A/S
Research Ascendis Pharma A/S (ASND) on Bullrun: market cap USD 16.61B, P/E 19.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerASND
- ExchangeNASDAQ
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 16.61B
- P/E19.3
- Financial periodQ1 2026
- RevenueEUR 246.60M
- Net incomeEUR 629.34M
- Free cash flow-EUR 7.72M
- Gross margin92.9%
Valuation Snapshot
latest market cap is USD 16.61B; P/E is 19.3.
Peer valuation comparison
Latest P/E is 19.28x versus a Healthcare sector median of 24.46x (21.2% below).
Latest P/E is 19.28x versus a Denmark median of 19.06x.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 720.13M | -EUR 228.03M | EUR 45.41M | 86.8% | -3.95 | EUR 616.04M | EUR 871.79M | -EUR 162.82M |
| FY2024 | EUR 363.64M | -EUR 378.08M | -EUR 307.62M | 87.8% | -6.87 | EUR 559.54M | EUR 856.62M | -EUR 105.71M |
| FY2023 | n/a | n/a | -EUR 469.80M | n/a | n/a | EUR 392.16M | EUR 644.27M | -EUR 145.70M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 16.61B | 19.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.09B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.24B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.13B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 6.96B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.64B | n/a | n/a | n/a |
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ascendis Pharma A/S's market cap?
Ascendis Pharma A/S's market capitalization is USD 16.61B.
What is Ascendis Pharma A/S's P/E ratio?
Ascendis Pharma A/S's price-to-earnings (P/E) ratio is 19.3.
What does Ascendis Pharma A/S do?
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.